Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

December 1, 2022

https://www.globenewswire.com/news-release/2022/12/01/2565879/0/en/Protara-Therapeutics-Announces-Trials-in-Progress-Poster-Presentation-for-the-ADVANCED-1-Trial-in-NMIBC-at-the-23rd-Annual-Meeting-of-the-Society-of-Urologic-Oncology.html

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the Annual Meeting of the Society of Urologic Oncology being held in San Diego, California from November 30, 2022 through December 2, 2022. The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Read more at globenewswire.com

Related news for (TARA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.